Synthetic peptide corresponding to a region of GAD67 (EC 220.127.116.11) shared between the mouse (P48318), rat (NP_058703) and human (Q99259) gene products conjugated to KLH.
It is important to note that, in our hands, we saw only a subpopulation of GABAergic neurons in various mouse brain structures, including cerebral cortex and cerebellar cortex, labeled with our anti-GAD-67 antibody. This was seen multiple times, and following steps to increase antibody penetration into the tissue. Although the basis of this mysterious subpopulation is unclear, we suspect that the epitope specifically recognized by this antibody on GAD-67 may be cryptic or absent in some inhibitory neurons.
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/1000 - 1/2000.
1/1000 - 1/2000.
Catalyzes the production of GABA.
Isoform 3 is expressed in pancreatic islets, testis, adrenal cortex, and perhaps other endocrine tissues, but not in brain.
Involvement in disease
Defects in GAD1 are the cause of cerebral palsy spastic quadriplegic type 1 (CPSQ1) [MIM:603513]. A non-progressive disorder of movement and/or posture resulting from defects in the developing central nervous system. Affected individuals manifest symmetrical, non-progressive spasticity and no adverse perinatal history or obvious underlying alternative diagnosis. Developmental delay, mental retardation and sometimes epilepsy can be part of the clinical picture.
Immunocytochemistry/Immunofluorescence analysis of e18 mouse neurosphere cells in culture labelling GAD67 (green) with ab75712. Cells were fixed with 4% paraformaldehyde. Red - rabbit anti-MAP2, Blue: DAPI nuclear stain.